IDEXX Laboratories (IDXX) Set to Announce Quarterly Earnings on Thursday

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to issue its quarterly earnings data before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of $1.36 per share for the quarter.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.13. The business had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. IDEXX Laboratories had a negative return on equity of 1,501.94% and a net margin of 17.33%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.01 EPS. On average, analysts expect IDEXX Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

NASDAQ:IDXX opened at $286.05 on Wednesday. The firm has a market cap of $24.43 billion, a P/E ratio of 67.15 and a beta of 0.86. The stock’s fifty day moving average price is $278.15. IDEXX Laboratories has a 52-week low of $176.11 and a 52-week high of $292.17. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81.

IDXX has been the subject of a number of recent research reports. Bank of America set a $300.00 price objective on IDEXX Laboratories and gave the stock a “buy” rating in a research report on Friday, June 21st. Zacks Investment Research cut Inflarx from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Guggenheim reiterated a “buy” rating and set a $95.00 price objective (up previously from $90.00) on shares of VF in a research report on Thursday, May 23rd. Canaccord Genuity reiterated a “speculative buy” rating and set a GBX 70 ($0.91) price objective on shares of Bacanora Lithium in a research report on Monday, July 1st. Finally, BidaskClub cut Zai Lab from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 26th. Eight research analysts have rated the stock with a buy rating, IDEXX Laboratories presently has a consensus rating of “Buy” and a consensus target price of $273.86.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 28,000 shares of IDEXX Laboratories stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $249.02, for a total value of $6,972,560.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Giovani Twigge sold 2,600 shares of IDEXX Laboratories stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $250.14, for a total value of $650,364.00. Following the completion of the sale, the insider now owns 12,595 shares of the company’s stock, valued at approximately $3,150,513.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,721 shares of company stock valued at $12,554,774. 2.70% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Hedge Funds

Earnings History for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with's FREE daily email newsletter.